Cyclo Therapeutics

CYTH50

Penny Stock

$0.72arrow_drop_up4.14%$0.02

Penny Stock

CYTH50

$0.72

arrow_drop_up4.14%$0.02

Penny Stock

Performance History

Key Stats
Open	$0.68
Prev. Close	$0.61
EPS	-0.82
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$20.05M
PE Ratio	-

	LOW	HIGH
Day Range	0.61	0.72
52 Week Range	0.59	2.12

Ratios







EPS	-0.82

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Cyclo Therapeutics (CYTH)

Cyclo Therapeutics, Inc. (CYTH) is a biotechnology company that focuses on developing and commercializing innovative drugs for the treatment of rare genetic diseases. The company's lead product candidate is Trappsol(R) Cyclo(TM), which is a proprietary formulation of hydroxypropyl beta cyclodextrin. This drug is being evaluated as a potential treatment for Niemann-Pick Disease Type C (NPC), a progressive and fatal genetic disorder characterized by the accumulation of cholesterol and other lipids in various organs of the body. Cyclo Therapeutics aims to address an unmet medical need in the NPC patient population, as there are currently no approved treatments for this devastating disease.

Cyclo Therapeutics, Inc. recently announced positive results from its Phase 1 clinical trial of Trappsol(R) Cyclo(TM) in NPC patients. The trial demonstrated that the drug was well-tolerated and showed promising signs of efficacy in reducing disease burden. These encouraging results have paved the way for the initiation of a Phase 2b/3 clinical trial, which is expected to begin enrollment in the near future. Cyclo Therapeutics is also exploring the potential of Trappsol(R) Cyclo(TM) in other indications, such as Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. N. Scott Fine
Headquarters: Gainesville
Employees: 9
Exchange: NASDAQ

Keep an eye on Cyclo Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Cyclo Therapeutics's (CYTH) price per share?

The current price per share for Cyclo Therapeutics (CYTH) is $0.73. The stock has seen a price change of $0.03 recently, indicating a 4.15% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Cyclo Therapeutics (CYTH)?

For Cyclo Therapeutics (CYTH), the 52-week high is $2.12, which is 191.21% from the current price. The 52-week low is $0.59, the current price is 23.39% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Cyclo Therapeutics (CYTH) a growth stock?

Cyclo Therapeutics (CYTH) has shown an average price growth of -6.65% over the past three years. It has received a score of 11 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cyclo Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Cyclo Therapeutics (CYTH) stock price performance year to date (YTD)?

As of the latest data, Cyclo Therapeutics (CYTH) has a year-to-date price change of -56.14%. Over the past month, the stock has experienced a price change of -7.25%. Over the last three months, the change has been -41.05%. Over the past six months, the figure is -48%.

help

Is Cyclo Therapeutics (CYTH) a profitable company?

Cyclo Therapeutics (CYTH) has a net income of -$20.06M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -4.58K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $1.08M, although specific revenue growth data is currently not available. Operating income is noted at -$20.05M. Furthermore, the EBITDA is -$21.14M.

help

What is the market capitalization of Cyclo Therapeutics (CYTH)?

Cyclo Therapeutics (CYTH) has a market capitalization of $20.06M. The average daily trading volume is 0.73, indicating the stock's liquidity and investor engagement.

News

PACIRA BIOSCIENCES

SHAWN CROSS

CHIEF FINANCIAL OFFICER

NON-OPIOID PAIN THERAPIES

Oct 21, 2024

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer

MERGERS AND ACQUISITIONS

SHAREHOLDER INVESTIGATIONS

FIDUCIARY DUTIES

FAIR VALUE

Sep 6, 2024

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CrossFirst Bankshares, Inc. (Nasdaq - CFB), Arch Resources, Inc. (NYSE - ARCH), Cyclo Therapeutics, Inc. (Nasdaq - CYTH), Vector Group Ltd. (NYSE - VGR)

VECTOR GROUP LTD.

ARCH RESOURCES, INC.

CYCLO THERAPEUTICS, INC.

RAFAEL HOLDINGS, INC.

MERGERS AND ACQUISITIONS

SHAREHOLDER RIGHTS

Aug 27, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VGR, ARCH, CYTH on Behalf of Shareholders

SHAREHOLDER INVESTIGATION

SECURITIES LAWS

FIDUCIARY DUTIES

MERGERS AND ACQUISITIONS